AC Immune to Receive CHF 24.6M Milestone from Janssen

TL;DR

AC Immune gets CHF 24.6M from J&J for Alzheimer's drug trial progress.

AI Summary

On September 17, 2024, AC Immune SA announced it will receive a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals, Inc. This payment is related to the Phase 2b Re-tain trial for their active-immunotherapy candidate ACI-35.030, now known as JNJ-2056, which targets preclinical Alzheimer's disease.

Why It Matters

This milestone payment validates the progress of AC Immune's Alzheimer's drug candidate and provides significant non-dilutive funding, potentially boosting investor confidence.

Risk Assessment

Risk Level: medium — While positive, the payment is tied to trial progress, and the ultimate success of the drug candidate remains uncertain.

Key Numbers

• CHF 24.6M — Milestone Payment (Received from Janssen for trial progress)

Key Players & Entities

• AC Immune SA (company) — Registrant
• Janssen Pharmaceuticals, Inc. (company) — Partner company
• Johnson & Johnson (company) — Parent company of Janssen
• CHF 24.6 million (dollar_amount) — Milestone payment amount
• September 17, 2024 (date) — Announcement date
• ACI-35.030 (drug_candidate) — AC Immune's Alzheimer's drug candidate
• JNJ-2056 (drug_candidate) — Renamed drug candidate

FAQ

Filing Documents

• dp218055_6k.htm (6-K) — 12KB
• dp218055_ex9901.htm (EX-99.1) — 21KB
• image_001.jpg (GRAPHIC) — 52KB
• 0000950103-24-013644.txt ( ) — 106KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F On September 17, 2024, AC Immune SA issued a press release announcing that it will receive the second Re ain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company. The milestone payment has been triggered by the rapid rate of prescreening in the potentially registrational Phase 2b Re ain trial investigating active-immunotherapy candidate ACI-35.030 (now called “JNJ-2056”) to treat preclinical (pre-symptomatic) Alzheimer’s disease (AD). With last December’s milestone payment, this brings the total milestone payments received for ACI-35.030 related to this trial to CHF 40 million. This Report on Form 6-K (other than Exhibit 99.1 hereto) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-227016, 333-249655, 333-255576 and 333-277940) and Form S-8 (File Nos. 333-213865, 333-216539 and 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated September 17, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AC IMMUNE SA By: /s/ Andrea Pfeifer Name: Andrea Pfeifer Title: Chief Executive Officer By: /s/ Christopher Roberts Name: Christopher Roberts Title: Chief Financial Officer Date: September 17, 2024

View Full Filing

View this 6-K filing on SEC EDGAR